Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$239 Mln
P/E Ratio
--
P/B Ratio
8.51
Industry P/E
--
Debt to Equity
0.28
ROE
-1.36 %
ROCE
-125.24 %
Div. Yield
0 %
Book Value
1.42
EPS
-5.92
CFO
$-963.47 Mln
EBITDA
$-1,132.99 Mln
Net Profit
$-1,164.09 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
DBV Technologies S.A. - ADR
| 193.85 | 46.45 | 102.68 | 33.14 | -10.81 | -32.08 | -28.45 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
DBV Technologies S.A. - ADR
| -67.28 | -37.71 | -4.38 | -38.93 | -75.51 | 66.67 | -73.71 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.64 | 200.22 | -- | 299.46 | |
| 7.14 | 191.83 | -- | -40.76 | |
| 1.60 | 229.53 | -- | -136.88 | |
| 0.58 | 19.23 | 5.35 | 33.7 |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed... Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France. Read more
CEO & Director
Mr. Daniel Tassé
CEO & Director
Mr. Daniel Tassé
Headquarters
Châtillon
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of DBV Technologies SA - ADR stood at $ 66 Mln as on 31-Dec-24
The share price of DBV Technologies SA - ADR is $9.08 (NASDAQ) as of 29-Apr-2025 16:00 EDT. DBV Technologies SA - ADR has given a return of -10.81% in the last 3 years.
DBV Technologies SA - ADR has a market capitalisation of $ 239 Mln as on 25-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of DBV Technologies SA - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the DBV Technologies SA - ADR and enter the required number of quantities and click on buy to purchase the shares of DBV Technologies SA - ADR.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
The CEO & director of Mr. Daniel Tassé. is DBV Technologies SA - ADR, and CFO & Sr. VP is Mr. Daniel Tassé.
There is no promoter pledging in DBV Technologies SA - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
23
|
|
|
20
|
|
|
18
|
|
|
2
|
| DBV Technologies S.A. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-135.96
|
|
Operating margin(%)
|
-4392.83
|
|
Net Margin(%)
|
-4436.06
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of DBV Technologies SA - ADR was $0 Mln.
$-0.09
(
